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reusable forceps, and also that they were more cost effec-
tive.
The use of disposable biopsy forceps eliminates the risk
of infection and of pyrogen or endotoxin reactions that may
arise if organic debris remains on reusable biopsy forceps
after sterilization.
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Proton Pump Inhibitors and Gastric
Acid Secretion
TO THE EDITOR: Proton pump inhibitors (PPIs) are the
most potent inhibitors of gastric acid secretion in use for the
treatment of various acid-related disorders. However, be-
cause of their unique pharmacology (1), these agents are
most effective after oral administration when the parietal
cell is stimulated to secrete acid in response to a meal.
Accordingly, PPIs should optimally be administered before
or with a meal. This regimen is required despite a prolonged
duration of action because the plasma half-life of PPIs is
quite short (2–3 h), and the use of single-dose oral PPIs in
fasting individuals does not reliably provide adequate acid
suppression. They should also not be used in conjunction with
histamine-2 receptor antagonists, somatostatin analogues,
prostaglandins, or other antisecretory agents until the anti-
secretory effects of the latter drugs have abated (1, 2).
Pantoprazole recently was approved by the United States
Food and Drug Administration as the only PPI for use as an
i.v. formulation in the United States. Omeprazole and, to
some extent, lansoprazole are used in other countries in this
manner. It is expected that pantoprazole will have at least
equivalent efficacy, even if the precise therapeutic role of
i.v. PPIs has not been firmly established. A recent report by
Lau et al. (3) on patients with upper GI hemorrhage due to
ulcers for whom endoscopic therapy was initially employed
to achieve hemostasis demonstrated that i.v. omeprazole
was effective in decreasing recurrent bleeding and hence the
need for surgical intervention. In this study, omeprazole was
administered as an 80-mg bolus followed by i.v. infusion at
a rate of 8 mg/h. Whether PPIs administered in a similar
manner will be effective in preventing GI hemorrhage as-
sociated with stress-related erosive syndrome (SRES) has
not yet been determined. Two recent studies in mechanically
ventilated patients suggested that an omeprazole-suspended
bicarbonate solution not only may prevent clinically signif-
icant SRES-induced hemorrhage, but is also safe and cost-
effective (4, 5). However, the study designs employed in
these trials were limited in scope, including nonrandomiza-
tion and open labeling, and patient numbers were small.
Omeprazole and lansoprazole are acid-labile prodrugs that
have been formulated as granules with an enteric coating
designed to dissolve at pH 5.5. Thus, with the bicarbonate
suspension, the protective enteric coating is dissolved. Al-
though the drug is purportedly protected from the acidic
environment in the gastric lumen by the bicarbonate, many
other factors may influence acid exposure, including the
amount of bicarbonate as well as the pH and volume of the
solution used to flush the suspension through a nasogastric
tube. It is therefore possible that the PPI released from the
granules undergoes acid-catalyzed conversion to the reac-
tive species, a thiophilic sulfenamide, with inactivation of
the drug before arrival at its intended target site (6, 7). PPIs
are prodrugs that, after systemic absorption, are targeted to
the highly acidic milieu of the secretory canaliculus of
secreting parietal cells (1, 8). It is in this structure that they
are normally activated to form the sulfenamide. Targeting
and, hence, local activation after oral dosing are best
achieved postprandially, when most parietal cells are active.
Because individuals at risk for the development of SRES are
generally fasting, these drugs would likely be less effective
in providing prolonged acid suppression unless adminis-
tered in a manner that maintains a plasma level exceeding
that generally achieved by oral dosing (1).
Although i.v. pantoprazole is currently approved by the
Food and Drugs Administration only for those individuals
with GERD who are unable to tolerate oral PPIs, it is quite
likely that it will prove beneficial and thus will be used
widely for other indications, including the prevention of
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recurrent hemorrhage due to ulcers and stress prophylaxis.
However, appropriate studies should be conducted to deter-
mine the effectiveness of various i.v. pantoprazole regimens
in different clinical scenarios. Until the completion of these
studies, however, based on the pharmacokinetic properties
of PPIs and the above omeprazole study (3), if the decision
is made to prescribe i.v. pantoprazole to prevent recurrent
hemorrhage associated with peptic ulcer, we recommend
that a loading dose of 80 mg be followed by a continuous i.v.
infusion of 8 mg/h. The cost associated with i.v. adminis-
tration is significant, and the regimen should thus be
changed to 40 mg p.o. before breakfast as soon as it is
deemed safe for the individual to consume food.
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Liver Cirrhosis in Erythropoietic
Protoporphyria: Improvement of Liver
Function With Ursodeoxycholic Acid
TO THE EDITOR: Erythropoietic protoporphyria (EPP) is
an inherited disorder of heme synthesis caused by deficiency
of the mitochondrial enzyme ferrochelatase. Chronic liver
disease is the most severe and rapidly progressive compli-
cation of EPP, requiring liver transplantation in some pa-
tients. The pathogenesis of liver damage in EPP is not clear.
Data from mouse models suggested that EPP causes an
abnormal bile composition, which was found to be cytotoxic
(1). In humans, cholestasis results from intracellular and
canalicular precipitation of protoporphyrin (2).
We report on a 74-yr-old female patient with a history of
photosensitivity beginning in early adolescence. Jaundice
and abnormal liver function parameters were first observed
10 yr before admission. EPP was diagnosed by a 1000-fold
increase of protoporphyrin in erythrocytes, when she was
referred to our hospital primarily because of jaundice,
weight loss, and decreased liver function of unknown origin.
Chronic viral, autoimmune, toxic, or other metabolic dis-
eases were excluded. Family history for photosensitivity or
liver disease was negative. On admission she had a more
than 15-fold elevation of total and direct bilirubin, a 7-fold
elevation of -glutamyltransferase, and a 2- to 3-fold ele-
vation of ALP and transaminases. Laboratory tests for he-
molysis were negative. Liver function was impaired, as
indicated by decreased PT (56%), cholinesterase activity
(1.4 kU/L), and serum albumin (27 g/L). Ultrasound showed
liver cirrhosis with a moderate amount of ascites requiring
diuretic treatment, and a moderate enlargement of the
spleen. Liver biopsy confirmed the EPP-related liver cirrho-
sis. Liver transplantation was critically discussed.
Because of pathophysiological considerations that liver
damage in EPP is related to cholestasis, we started an
experimental treatment with ursodeoxycholic acid (UDCA)
(18 mg/kg body weight), which was reduced to 10 mg/kg
body weight and 5 mg/kg body weight after 3 and 6 months
of treatment, respectively. After 2 wk of treatment we ob-
served a marked reduction of cholestasis parameters, with a
further improvement to normal values within the following
6 months (Fig. 1). During the same period of time PT,
cholinesterase activity, and serum albumin improved to
normal values. Diuretic treatment was discontinued without
reoccurence of ascites. The Child-Pugh score was initially
10 (Child C) and normalized within 6 months of treatment
to 5 points (Child A). Photosensitivity markedly improved.
Re-evaluation of the patient 1 yr after onset of UDCA
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